You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Request a contact

Stay informed

Live Chat

Dovato

Dovato (dolutegravir/lamivudine) is now available in Ireland for the treatment of HIV-1 in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. 3

Vocabria-Rekambys

Vocabria (cabotegravir) injection is indicated, in combination with rilpivirine injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class. 4

Administration Video

Administration Video

This video will take you through the process of preparing and administering Vocabria + Rekambys

Learn More

Our Medicines

Explore our medicines

Explore our portfolio of dolutegravir-based medicines including the summary of product characteristics and patient information guides.

Learn More

For further information on any of these products see the links to the Summary of Product Characteristics available at the top of this page.

Request a meeting with Viiv representative

References:

  1. Cahn P et al. J Acquir Immunde Defic Syndr . 2020;83(3):310-318
  2. van Wyk J;IAS;2019;1-16
  3. Dovato Summary of Characteristics. Available at www.medicines.ie. Last accessed: September 2022
  4. Vocabria Summary of Characteristics. Available at www.medicines.ie Last accessed: September 2022.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.

REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.

All other trademarks are owned by the ViiV Healthcare group, or its licensor.